Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
about
Bacterial outer membrane vesicles and vaccine applicationsPotential Roles of Fungal Extracellular Vesicles during InfectionOuter membrane vesicles as platform vaccine technologyThrough the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungiRole of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal diseaseA novel approach for purification and selective capture of membrane vesicles of the periodontopathic bacterium, Porphyromonas gingivalis: membrane vesicles bind to magnetic beads coated with epoxy groups in a noncovalent, species-specific mannerStructure of the C-terminal Domain of Neisseria Heparin Binding Antigen (NHBA), One of the Main Antigens of a Novel Vaccine against Neisseria meningitidisIntranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in miceAn OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and ToxicityMolecular epidemiology of Neisseria meningitidis serogroup B in BrazilOuter membrane vesicles displaying engineered glycotopes elicit protective antibodiesEmerging experience with meningococcal serogroup B protein vaccines.Recent Progress in the Prevention of Serogroup B Meningococcal Disease.Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis.Review of meningococcal group B vaccines.Virulence and immunomodulatory roles of bacterial outer membrane vesicles.Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis.The Therapeutic Benefit of Bacterial Membrane Vesicles.Outer membrane vesicles as a candidate vaccine against edwardsiellosis.Outer membrane vesicles of Porphyromonas gingivalis elicit a mucosal immune response.A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I).Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosisImmunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae.Bexsero® chronicle.Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine developmentImproved production process for native outer membrane vesicle vaccine against Neisseria meningitidis.Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins.Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteinsRecognition of Neisseria meningitidis by the long pentraxin PTX3 and its role as an endogenous adjuvant.The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection.From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease.Characterization of outer membrane vesicles from Brucella melitensis and protection induced in mice.Optimization of Molecular Approaches to Genogroup Neisseria meningitidis Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B VaccinesImmunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvantCharacterization and Vaccine Potential of Outer Membrane Vesicles Produced by Haemophilus parasuis.
P2860
Q24568229-9F8E1D75-CFCD-4D9D-A491-1621740B6CE2Q26743448-E326EDDB-F6D0-4095-B0F2-ADF61164FE02Q26766539-A9D7A12E-2EDC-4382-80C7-7E5BE39CE1BFQ26795676-91D35712-A9F3-46C4-B036-42F2C0993384Q26995760-D23B6D5F-7B6D-4842-AB13-E20D55FD9143Q27339403-8B33F5C0-C423-4E73-B487-044200E7297AQ27674699-8144AEF2-B6AA-4A37-A64A-F970DABCF5F1Q28482083-9F489E71-3DC9-4F01-AA42-E0B4B30D2E43Q28607442-6A412848-C792-477D-9EC9-FE7E51F52A16Q28731309-D458D15D-C0A6-4A45-9521-23486F36B5C9Q28831290-75AC5E44-5826-4F8D-B27E-4A1F26844B5DQ30234958-A00BAC31-5E30-4629-88E8-5E6F692F7A57Q30235040-B21A913A-A066-4326-8C0F-BBF4DEF7F9D5Q30248749-D8E2CE41-FBCC-4B02-B0DF-4815DD8E4D0AQ33601907-0A106749-F110-4851-8672-783D5C82F42CQ33646965-02A1A0D1-4670-4307-8D7A-6E182199E6A8Q33704480-540833C2-D39B-46E9-B540-0437A06ED0E0Q33784386-6182688F-2EB6-4994-B4A3-3BC089B19C03Q33839021-E434C02B-48FF-48FB-843E-E8A80CB8E4BFQ33847392-7ADDD059-BDD9-4B89-9F9A-4F1B402CB6EAQ34056091-FFD09843-9F82-45A2-9823-7A693213E779Q34291176-E7934192-4360-4D98-AC7F-9FEF5A730703Q34334767-FD654FEA-E8A2-4E25-8294-3D7080F493A8Q34529570-8E5FA0F1-AD8F-4FC9-98B0-AC71C16DF95EQ34562726-87AE5B1E-94D3-48A9-A5C2-DCD25A15633EQ34571107-D6A599E2-8CA1-47E6-8DB2-61D282848A03Q34761285-9678D277-BE6E-45E1-B17F-6CBFB5F083A0Q34889968-0C49CD9C-DAB8-4F76-A301-B616367E1EBAQ34955474-73DD4BE1-BE46-4972-BC8C-4B09388EB71CQ35043042-41F0E1D1-4A7D-43D1-B1E4-23E3CCE17308Q35075181-B395F0EB-D5B8-4225-A823-5ABBAF071F26Q35191828-32800DF8-7001-410A-B652-5C156DFBD832Q35191903-BA4D888C-2637-4545-85FD-E094935A205FQ35375333-537CCAE4-D375-4B92-9D07-AC6D1A6895BEQ35453441-1F3F57F9-7694-4DEE-93A9-33D4C6B7C985Q35661526-B1308BD3-DEE2-4D15-A455-D949147731A7Q35683382-AB86401C-D52F-4921-9954-359DA2581153Q35887131-A9ECE35E-0CA6-4B59-B4E9-7B468E482E1AQ35887397-5456A925-B9D3-42D2-8DF2-51472810B68AQ35940925-1C787CA6-0634-4E6A-A908-F764662383ED
P2860
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Properties and clinical perfor ...... s from Neisseria meningitidis.
@ast
Properties and clinical perfor ...... s from Neisseria meningitidis.
@en
Properties and clinical perfor ...... s from Neisseria meningitidis.
@nl
type
label
Properties and clinical perfor ...... s from Neisseria meningitidis.
@ast
Properties and clinical perfor ...... s from Neisseria meningitidis.
@en
Properties and clinical perfor ...... s from Neisseria meningitidis.
@nl
prefLabel
Properties and clinical perfor ...... s from Neisseria meningitidis.
@ast
Properties and clinical perfor ...... s from Neisseria meningitidis.
@en
Properties and clinical perfor ...... s from Neisseria meningitidis.
@nl
P2093
P1433
P1476
Properties and clinical perfor ...... s from Neisseria meningitidis.
@en
P2093
Concepcion Campa Huergo
Diana Martin
Einar Rosenqvist
Jane O'Hallahan
Johan Holst
Philipp Oster
P356
10.1016/J.VACCINE.2009.04.071
P407
P478
27 Suppl 2
P577
2009-05-28T00:00:00Z